Literature DB >> 7809109

Molecular evidence for two forms of Crohn disease.

E C Gilberts1, A J Greenstein, P Katsel, N Harpaz, R J Greenstein.   

Abstract

Recent epidemiological evidence suggests that there are two forms of Crohn disease (CD): perforating and nonperforating. We hypothesized that, just as with tuberculoid and lepromatous leprosy, differences in the two forms of CD would be both identified and determined by differences in the host immune response. Resected intestinal tissue from control patients as well as perforating and nonperforating CD patients was evaluated for mRNA levels. We employed 32P PCR amplification with published or custom-designed primers of a housekeeping gene (beta-actin); a human T-cell marker (CD3-delta); and the cytokines tumor necrosis factor alpha, transforming growth factor beta, granulocyte/macrophage colony-stimulating factor, interleukin (IL) 1 beta, IL-1ra, and IL-6. Differences were identified with IL-1 beta (control = 162 +/- 57 vs. perforating = 464 +/- 154 vs. nonperforating = 12,582 +/- 4733; P < or = 0.02) and IL-1ra (control = 1337 +/- 622 vs. perforating = 2194 +/- 775 vs. nonperforating = 9715 +/- 2988; P < or = 0.02). These data corroborate the epidemiological observation that there are two forms of CD. Nonperforating CD, the more benign form, is associated with increased IL-1 beta and IL-1ra mRNA expression. We conclude that it is the host immune response that determines which form of CD becomes manifest in any given individual and discuss the investigative, diagnostic, and therapeutic implications of these observations.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7809109      PMCID: PMC45511          DOI: 10.1073/pnas.91.26.12721

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

Review 1.  Current concepts in the pathogenesis of Crohn's disease.

Authors:  P R Gibson
Journal:  J Gastroenterol Hepatol       Date:  1990 Jan-Feb       Impact factor: 4.029

Review 2.  Pathogenic factors in inflammatory bowel disease. 2. Crohn's disease.

Authors:  P Pavli; P R Gibson
Journal:  Dig Dis       Date:  1992       Impact factor: 2.404

Review 3.  The role of ciclosporin therapy in Crohn's disease. A review.

Authors:  J Brynskov
Journal:  Dig Dis       Date:  1991       Impact factor: 2.404

Review 4.  Pathogenetic and clinical relevance of cytokines in inflammatory bowel disease.

Authors:  R B Sartor
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

5.  Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease.

Authors:  C Stevens; G Walz; C Singaram; M L Lipman; B Zanker; A Muggia; D Antonioli; M A Peppercorn; T B Strom
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

6.  Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms.

Authors:  A J Greenstein; P Lachman; D B Sachar; J Springhorn; T Heimann; H D Janowitz; A H Aufses
Journal:  Gut       Date:  1988-05       Impact factor: 23.059

7.  IL-1 and IFN-gamma increase vascular permeability.

Authors:  S Martin; K Maruta; V Burkart; S Gillis; H Kolb
Journal:  Immunology       Date:  1988-06       Impact factor: 7.397

8.  Soluble interleukin-2 receptor, interleukin-6 and interleukin-1 beta in patients with Crohn's disease and ulcerative colitis: preoperative levels and postoperative changes of serum concentrations.

Authors:  G Schürmann; M Betzler; S Post; C Herfarth; S Meuer
Journal:  Digestion       Date:  1992       Impact factor: 3.216

9.  Defining protective responses to pathogens: cytokine profiles in leprosy lesions.

Authors:  M Yamamura; K Uyemura; R J Deans; K Weinberg; T H Rea; B R Bloom; R L Modlin
Journal:  Science       Date:  1991-10-11       Impact factor: 47.728

10.  High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis.

Authors:  Y R Mahida; L Kurlac; A Gallagher; C J Hawkey
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

View more
  10 in total

1.  Fecal beta-D-galactosidase production and Bifidobacteria are decreased in Crohn's disease.

Authors:  C Favier; C Neut; C Mizon; A Cortot; J F Colombel; J Mizon
Journal:  Dig Dis Sci       Date:  1997-04       Impact factor: 3.199

Review 2.  Pharmacogenetic biomarkers of response in Crohn's disease.

Authors:  T M Linares-Pineda; M Cañadas-Garre; A Sánchez-Pozo; M Á Calleja-Hernández
Journal:  Pharmacogenomics J       Date:  2017-06-20       Impact factor: 3.550

3.  Disseminated aseptic abscesses associated with Crohn's disease: a new entity?

Authors:  M André; O Aumaître; T Papo; J L Kemeny; D Vital-Durand; H Rousset; J Ninet; P Pointud; F Charlotte; B Godeau; J Schmidt; J C Marcheix; J C Piette
Journal:  Dig Dis Sci       Date:  1998-02       Impact factor: 3.199

4.  Interleukin-2 fusion protein (DAB389IL-2) selectively targets activated human peripheral blood and lamina propria lymphocytes.

Authors:  A Bousvaros; A C Stevens; T B Strom; J Murphy; J T Lamont
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

5.  Keratinocyte growth factor is highly overexpressed in inflammatory bowel disease.

Authors:  M Brauchle; M Madlener; A D Wagner; K Angermeyer; U Lauer; P H Hofschneider; M Gregor; S Werner
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

6.  Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease.

Authors:  E Louis; A Collard; A F Oger; E Degroote; F A Aboul Nasr El Yafi; J Belaiche
Journal:  Gut       Date:  2001-12       Impact factor: 23.059

7.  Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR).

Authors:  M Niessner; B A Volk
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

8.  On the etiology of Crohn disease.

Authors:  D Mishina; P Katsel; S T Brown; E C Gilberts; R J Greenstein
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

9.  Clinical subtypes of Crohn's disease according to surgical outcome.

Authors:  S E Greenway; M A Buckmire; C Marroquin; L Jadon; R H Rolandelli
Journal:  J Gastrointest Surg       Date:  1999 Mar-Apr       Impact factor: 3.267

10.  PI3K/Akt/mTOR signaling & its regulator tumour suppressor genes PTEN & LKB1 in human uterine leiomyomas.

Authors:  Annu Makker; Madhu Mati Goel; Abbas Ali Mahdi; Vikram Bhatia; Vinita Das; Anjoo Agarwal; Amita Pandey
Journal:  Indian J Med Res       Date:  2016-05       Impact factor: 2.375

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.